Watch SER. Know when insiders buy.
One email the day a filing lands. Free.
SER
Serina Therapeutics, Inc.
2.09
−0.05 −2.34%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $53.1MP/E —DIV YIELD —FCF YIELD -39.94%REV TTM —NET INCOME −$21.2MNET CASH $11.9M52W 1.28 – 5.63SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$6.8M | −$6.4M | — | -0.55 | −$6.7M | $28K | −$6.7M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | — | −$6.9M | — | -0.58 | −$4.6M | $25K | −$4.6M | May 14 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$6.2M | −$3.3M | — | -0.31 | −$6M | $0 | −$6M | Mar 25 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$6.4M | −$4.6M | −425.2% | -0.45 | −$3.9M | $13K | −$3.9M | Nov 13 |
| Q2 2025 · Jun 30 | $130K | +154.9% | — | −$5.6M | −$6.4M | −223.9% | -0.66 | −$3.8M | $46K | −$3.8M | Aug 13 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$5.9M | −$4.8M | — | -0.49 | −$4.3M | $0 | −$4.3M | May 14 |
| Q4 2024 · Dec 31derived | −$14K | −100.5% | — | −$5.5M | −$2.7M | −360.7% | -0.27 | −$4.6M | $5K | −$4.6M | Mar 25 |
| Q3 2024 · Sep 30 | $14K | −51.7% | — | −$5.3M | $1.4M | −19.5% | 0.13 | −$3M | $3K | −$3M | Nov 13 |
| Q2 2024 · Jun 30 | $51K | — | — | −$3.9M | $5.2M | — | 0.51 | −$8M | $0 | −$8M | Aug 11 |
| Q1 2024 · Mar 31 | $5K | — | — | −$2.3M | −$15M | — | -5.38 | −$1.6M | $14K | −$1.6M | May 8 |
| Q4 2023 · Dec 31derived | $3.1M | — | 1.8% | $241K | $1.1M | — | 0.16 | $121K | $70K | $51K | Mar 24 |
| Q3 2023 · Sep 30 | $29K | — | 117.2% | −$1.5M | $1.8M | — | 0.23 | −$1M | $119K | −$1.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $130K | — | −$24M | −$19.2M | -14755.4% | -1.91 | −$18M | $59K | −$18M | — | — |
| FY2024 · to Dec 31 | $56K | — | −$17M | −$11.1M | -19894.6% | -1.51 | −$17.1M | $22K | −$17.2M | — | — |
| FY2023 · to Dec 31 | $3.2M | 3.2% | −$3.1M | $5.3M | 167.1% | 0.73 | −$2.5M | $504K | −$3M | — | — |
| FY2022 · to Dec 31 | $34K | 61.8% | −$7M | −$10.5M | -30770.6% | -9.70 | −$5.9M | — | — | — | — |
| FY2021 · to Dec 31 | $144K | 86.8% | −$7.9M | −$8.7M | -6024.3% | -0.23 | −$7.9M | — | — | — | — |
| FY2020 · to Dec 31 | $361K | 92.8% | −$10.1M | −$10.9M | -3009.7% | -0.29 | −$7.8M | $20K | −$7.8M | — | — |
Every number comes from Serina Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.